JNK Inhibitor VIII

Cat. No.: HY-107598

CAS No.: 894804-07-0

Molecular Formula: $C_{18}H_{20}N_4O_4$

Molecular Weight: 356.38

Target: JNK

Pathway: MAPK/ERK Pathway

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (701.50 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.8060 mL	14.0300 mL	28.0599 mL
	5 mM	0.5612 mL	2.8060 mL	5.6120 mL
	10 mM	0.2806 mL	1.4030 mL	2.8060 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

JNK Inhibitor VIII (TCS JNK 6o) is a c-Jun N-terminal kinases (JNK-1, -2, and -3) inhibitor with K_i values of 2 nM, 4 nM, 52 nM, respectively, and has IC_{50} values of 45 nM and 160 nM for JNK-1 and -2, respectively[1].

IC_{50} & Target

JNK1 2 nM (Ki)	JNK1 45 nM (IC_{50})	JNK2 4 nM (Ki)	JNK2 160 nM (IC_{50})
JNK3 52 nM (Ki)			

In Vitro

JNK Inhibitor VIII (TCS JNK 6o) shows over 1000- fold selective for JNK-1 and -2 over other MAP kinases including ERK2, p38 α, and p38δ[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Life Sci. 2020 Sep 1;256:117955.
- Microvasc Res. 2022 Feb 9;141:104338.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Szczepankiewicz BG, et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA